Caribou Biosciences, Inc. (CRBU)

NASDAQ: CRBU · IEX Real-Time Price · USD
5.09
-0.17 (-3.23%)
At close: Sep 22, 2023, 4:00 PM
5.16
+0.07 (1.38%)
Pre-market: Sep 25, 2023, 8:16 AM EDT
-3.23%
Market Cap 449.37M
Revenue (ttm) 10.50M
Net Income (ttm) -111.20M
Shares Out 88.28M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,372
Open 5.29
Previous Close 5.26
Day's Range 5.06 - 5.29
52-Week Range 3.96 - 11.52
Beta 1.94
Analysts Strong Buy
Price Target 24.25 (+376.42%)
Earnings Date Nov 7, 2023

About CRBU

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 23, 2021
Employees 137
Stock Exchange NASDAQ
Ticker Symbol CRBU
Full Company Profile

Financial Performance

In 2022, CRBU's revenue was $13.85 million, an increase of 44.31% compared to the previous year's $9.60 million. Losses were -$99.42 million, 48.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is $24.25, which is an increase of 376.42% from the latest price.

Price Target
$24.25
(376.42% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's pa...

26 days ago - GlobeNewsWire

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 tria...

6 weeks ago - GlobeNewsWire

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of a...

2 months ago - GlobeNewsWire

Caribou Biosciences offers more stock, and shares fall

Shares of Caribou Biosciences Inc. CRBU, +4.90% tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million share offering. The company, which focuses on genome e...

2 months ago - Market Watch

Caribou's cell therapy shows promise in early-stage cancer study

Caribou Biosciences Inc said on Thursday its experimental CAR T-cell therapy helped clear all signs or decrease tumor size in 94% of patients being treated for a type of cancer in the lymph nodes in a...

2 months ago - Reuters

Caribou Biosciences Announces Proposed Public Offering of Common Stock

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced...

2 months ago - GlobeNewsWire

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate,...

2 months ago - GlobeNewsWire

Pfizer Just Invested $25 million In This Biotech

Shares of Caribou Biosciences NASDAQ: CRBU were up 45% yesterday after Pfizer NYSE: PFE made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million shares of C...

Other symbols: PFE
2 months ago - MarketBeat

Pfizer makes equity investment in Caribou Biosciences

Pfizer has invested $25 million to buy a minority stake in Caribou Biosciences , making it the latest small biotechnology firm to attract the pharmaceutical giant's interest.

Other symbols: PFE
2 months ago - Reuters

Caribou Biosciences stock soars after Pfizer buys stock priced at a 31% premium

Shares of Caribou Biosciences Inc. CRBU ran up 21.3% toward a three-month high in premarket trading Thursday, after the genome-editing biopharmaceutical company said drug giant Pfizer Inc. has made a ...

Other symbols: PFE
2 months ago - Market Watch

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

-- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou's ...

Other symbols: PFE
2 months ago - GlobeNewsWire

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQ: CRBU...

3 months ago - Business Wire

Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at...

4 months ago - GlobeNewsWire

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

-- Dr. Schuster is a world-renowned hematologist and pioneer in  CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadin...

4 months ago - GlobeNewsWire

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML ...

5 months ago - GlobeNewsWire

CRBU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 11, 2023 in the Class Action Filed on Behalf of Caribou Biosciences, Inc. Shareholders

NEW YORK , April 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU) alleging that ...

5 months ago - PRNewsWire

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Caribou Investors of a Lead Plaintiff Deadline of April 11, 2023

NEW YORK , April 10, 2023 /PRNewswire/ -- Attention Caribou Biosciences, Inc. ("Caribou") (NASDAQ: CRBU) shareholders:

6 months ago - PRNewsWire

CRBU IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 11 Deadline in Securities Class Action - CRBU

NEW YORK , April 6, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or ...

6 months ago - PRNewsWire

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Caribou Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 11, 2023 - (NASDAQ: CRBU)

NEW YORK , April 5, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. Shareholders who purchased shares of CRBU during the class period l...

6 months ago - PRNewsWire

Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

-- CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 -- BERKELEY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clini...

6 months ago - GlobeNewsWire

CRBU SHAREHOLDER ALERT: Jakubowitz Law Reminds Caribou Shareholders of a Lead Plaintiff Deadline of April 11, 2023

NEW YORK , March 31, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). To ...

6 months ago - PRNewsWire

CRBU LAWSUIT ALERT: Levi & Korsinsky Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , March 30, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. CLASS ...

6 months ago - PRNewsWire

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

NEW YORK , March 24, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or ...

6 months ago - PRNewsWire

CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)

Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlie...

6 months ago - PRNewsWire

ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

NEW YORK , March 16, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or...

6 months ago - PRNewsWire